A Randomized, Double-blind, Placebo Controlled Dose-ranging Study to Determine the Effect on MRI Lesions and Safety of A4I Antagonist in Relapsing Multiple Sclerosis.
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 17 Feb 2017
At a glance
- Drugs RO 0506997 (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Sponsors Roche
- 10 Oct 2005 New trial record.